6 stories mentioning CRDFUpdated 2h ago
Every FINWIRES story that references CRDF, newest first.
Gary W Pace, Director, on July 14, 2026, executed a purchase for 687,285 shares in Cardiff Oncology (CRDF) for $1,000,000. Following the Form 4 filing with the SEC, Pace has control over a total of 2,043,661 common shares of the company, with 2,043,661 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1213037/000119312526306083/xslF345X05/ownership.xml
Healthcare stocks declined late Monday afternoon, with the NYSE Healthcare Index falling 1.4% and the State Street Health Care Select Sector SPDR ETF (XLV) dropping 1.1%.The iShares Biotechnology ETF (IBB) shed 1.4%.In corporate news, Cardiff Oncology (CRDF) shares tumbled past 21% after HC Wainwright downgraded the stock to neutral from buy, and TD Cowen to hold from buy.GRAIL (GRAL) stock dropped 9.7% after the company said the NHS-Galleri trial of its Galleri multi-cancer early detection test missed its primary endpoint.Jasper Therapeutics (JSPR) shares tumbled 32% after the firm said its board has launched a review of strategic alternatives, including a sale of assets, a sale of the company, merger, or an orderly wind-down of operations.Edgewise Therapeutics (EWTX) has agreed to sell its muscular dystrophy business to Servier for up to $2.65 billion, Servier said Monday. Edgewise shares jumped past 13%.
Healthcare stocks declined late Monday afternoon, with the NYSE Healthcare Index falling 1.4% and the State Street Health Care Select Sector SPDR ETF (XLV) dropping 1.1%.The iShares Biotechnology ETF (IBB) shed 1.4%.In corporate news, Cardiff Oncology (CRDF) shares tumbled 22% after HC Wainwright downgraded the stock to neutral from buy, and TD Cowen downgraded the stock to hold from buy.
Cardiff Oncology (CRDF) shares fell 23% in Monday trading after HC Wainwright downgraded the stock to neutral from buy.TD Cowen downgraded the stock to hold from buy.Intraday volume topped 5.21 million shares, compared with the daily average of 781,884.Price: $1.46, Change: $-0.44, Percent Change: -23.16%
Cardiff Oncology (CRDF) has an average rating of overweight and mean price target of $8.36, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
Cardiff Oncology (CRDF) has an average rating of buy and mean price target of $8.36, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
